Ovarian cancer in the elderly;Spécificité du cancer de l'ovaire chez la personne âgée

Oncologie

Volumn 10, Issue 1, 2008, Pages 3-7

  Falandry, C ^a   You, B ^a   Morel Soldner, I ^a   Bonnefoy, M ^a   Pujade Lauraine, E ^b   Freyer, G ^a  

^a UNIVERSITÉ LYON 1   (France)

^b HÔTEL DIEU   (France)

Author keywords

Elderly; Geriatric assessment; Ovarian cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL;

AGING; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER THERAPY; CYTOREDUCTIVE SURGERY; GERIATRIC ASSESSMENT; GERIATRIC CARE; GERIATRICS; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; LAPAROTOMY; OVARY CANCER; PROGNOSIS; VALIDATION STUDY;

EID: 39049146899     PISSN: 12923818     EISSN: 17652839     Source Type: Journal    
DOI: 10.1007/s10269-007-0781-3     Document Type: Article

References (42)

1. Bouchardy C, Rapiti E, Blagojevic S, et al. (2007) Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol 25: 1858-1869
2. Bruchim I, Altaras M, Fishman A (2002) Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer. Gynecol Oncol 86: 274-278
3. Ceccaroni M, D'Agostino G, Ferrandina G, et al. (2002) Gynecological malignancies in elderly patients: is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study. Gynecol Oncol 85: 445-450
4. Chiara S, Lionetto R, Vincenti M, et al. (2001) Advanced ovarian cancer in the elderly: results of consecutive trials with cisplatin-based chemotherapy. Crit Rev Oncol Hematol 37: 27-34
5. Delgado G, Oram DH, Petrilli ES (1984) Stage III epithelial ovarian cancer: the role of maximal surgical reduction. Gynecol Oncol 18: 293-298
6. Du Bois A, Luck HJ, Meier W, et al. (2003) A randomized clinical trial of cisplatin-paclitaxel versus carboplatin-paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95: 1320-1329
7. Du Bois A, Rochon J, Lamparter C, Pfisterer J (2005) Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer 15: 183-191
8. Eisenhauer EL, Tew WP, Levine DA, et al. (2007) Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. Gynecol Oncol 106: 381-387
9. Extermann M, Aapro M, Bernabei R, et al. (2005) Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55: 241-252
10. Freyer G, Geay JF, Touzet S, et al. (2005) Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol 16: 1795-1800
11. Giovanazzi-Bannon S, Rademaker A, Lai G, et al. (1994) Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center study. J Clin Oncol 12: 2447-2452
12. Grover SA, Cook EF, Adam J, et al. (1989) Delayed diagnosis of gynecologic tumors in elderly women: relation to national medical practice patterns. Am J 86: 151-157
13. Hutchins LF, Unger JM, Crowley JJ, et al. (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341: 2061-2067
14. Kyrgiou M, Salanti G, Pavlidis N, et al. (2006) Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst 98: 1655-1663
15. Le T, Leis A, Pahwa P, et al. (2004) Quality of life evaluations in patients with ovarian cancer during chemotherapy treatment. Gynecol Oncol 92: 839-844
16. Lichtinger M, Averette H, Penalver M, et al. (1986) Major surgical procedures for gynecologic malignancy in elderly women. South Med J 79: 1506-1510
17. Lichtman SM, Zaheer W, Gal D, et al. (1996) No increased risk of Taxol toxicity in older patients. J Am Geriatr Soc 44: 472-474
18. McGuire WP, Hoskins WJ, Brady MF, et al. (1996) Cyclophosphamide- cisplatin versus paclitaxel-cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 23: 40-47
19. Newcomb PA, Carbone PP (1993) Cancer treatment and age: patient perspectives. J Natl Cancer Inst 85: 1580-1584
20. NIH consensus conference (1995) Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 273: 491-497
21. Omura G, Blessing JA, Ehrlich CE, et al. (1986) A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer 57: 1725-1730
22. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002, 360: 505-515
23. Petignat P, Fioretta G, Verkooijen HM, et al. (2004) Poorer survival of elderly patients with ovarian cancer: a population-based study. Surg Oncol 13: 181-186
24. Repetto L, Fratino L, Audisio RA, et al. (2002) Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 20: 494-502
25. Repetto L, Venturino A, Vercelli M, et al. (1998) Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions. Cancer 82: 760-765
26. Registre des essais cliniques français en cancérologie. http://www.e-cancer.fr Rubrique Les essais cliniques Novembre 2007
27. Ries LA, Eisner MP, Kosary CL, et al. (2002) SEER cancer statistics review, 1973-1999. http://seer.cancer.gov/csr/1973_1999, Bethesda, MD: National Cancer Institute
28. Ries LA (1993) Ovarian cancer. Survival and treatment differences by age. Cancer 71: 524-529
29. Spriggs DR (2001) Ovarian cancer as a chronic disease: a new treatment paradigm. Highlights of a roundtable discussion. Cancer Control 5-7; discussion 8-18
30. Sundararajan V, Hershman D, Grann VR, et al. (2002) Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol 20: 173-178
31. Susini T, Scambia G, Margariti PA, et al. (1999) Gynecologic oncologic surgery in the elderly: a retrospective analysis of 213 patients. Gynecol Oncol 75: 437-443
32. Thigpen T, Stuart G, du Bois A, et al. (2005) Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens. Ann Oncol 16Suppl 8: 13-19
33. Trédan O, Geay JF, Touzet S, et al. (2007) Carboplatin- cyclophosphamide or carboplatin-pacitaxel in elderly with advanced ovarian cancer? Analysis of two consecutive trials from the GINECO. Ann Oncol 18
34. Trédan O, Geay JF, Touzet S, et al. (2006) Carboplatin- cyclophosphamide or carboplatin-pacitaxel in elderly with advanced ovarian cancer? Analysis of two consecutive trials from the GINECO. Ann Oncol (In press)
35. Uyar D, Frasure HE, Markman M, et al. (2005) Treatment patterns by decade of life in elderly women (≥ 70 years of age) with ovarian cancer. Gynecol Oncol 98: 403-408
36. Venesmaa P, Ylikorkala O (1992) Morbidity and mortality associated with primary and repeat operations for ovarian cancer. Obstet Gynecol 79: 168-172
37. Villella JA, Chaudhry T, Pearl ML, et al. (2002) Comparison of tolerance of combination carboplatin and paclitaxel chemotherapy by age in women with ovarian cancer. Gynecol Oncol 86: 316-322
38. Wimberger P, Lehmann N, Kimmig R, et al. (2006) Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGOOVAR). Gynecol Oncol 100: 300-307
39. Wright JD, Herzog TJ, Powell MA (2004) Morbidity of cytoreductive surgery in the elderly. Am J Obstet Gynecol 190: 1398-1400
40. Yancik R (1993) Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 71: 517-523
41. Young R, Fuks Z, Hoskins W (1989) Cancer of the ovary. Cancer principles in Practice of Oncology, De VitaVT Jr., Hellman S, Rosenberg SA Eds 1162-1196
42. Zola P, Ferrero A (2007) Is carboplatin-paclitaxel combination the standard treatment of elderly ovarian cancer patients? Ann Oncol (In press)